Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a meta …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing …
G Scioscia, CC De Pace, G Giganti, P Tondo… - Irish Journal of Medical …, 2023 - Springer
Abstract Background The SARS-CoV-2 pandemic has prompted clinicians to develop an
early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies …
early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Why molnupiravir fails in hospitalized patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2022 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …
Real-world use of molnupiravir in the treatment of outpatients with SARS-CoV-2 infection—a patient profile based on the experience of a tertiary infectious disease …
A Streinu-Cercel, VD Miron, AA Oană, M Irimia… - Pharmaceuticals, 2022 - mdpi.com
During the current pandemic, the gap between fundamental research and clinical practice
has been narrowing at a faster pace than ever before. While clinical trials play the main role …
has been narrowing at a faster pace than ever before. While clinical trials play the main role …
[HTML][HTML] The effect of molnupiravir on post-acute outcome of COVID-19 survivors
We read with great interest the review article by Gary et al., in which they raised several
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Y Suzuki, Y Shibata, H Minemura, T Nikaido… - Clinical and …, 2023 - Springer
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Safety profile of molnupiravir in the treatment of COVID-19: A descriptive study based on FAERS data
G Santi Laurini, N Montanaro, D Motola - Journal of Clinical Medicine, 2022 - mdpi.com
Concerns have been raised about the actual benefit and safety of molnupiravir, a new
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …
antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional …